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Introduction
Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common malignancy, with 650 000 new cases and 350 000 HNSCC-related deaths reported annually worldwide [1, 2] . HNSCC are curable, if diagnosed at early stages (I and II); however, the majority of HNSCC present with locally advanced disease. The mortality rate of patients with locally advanced tobacco-induced HNSCC, especially heavy smokers with T4 tumor size or advanced nodal stage, remains high despite advances in treatment [3] . Certainly, there is a great need to improve outcomes of locally advanced HNSCC by identifying patients at high risk for relapse that may benefit from adjuvant therapy.
Circulating tumor cells (CTCs) are considered indicators of residual disease and thus are associated with an increased risk of metastasis [4, 5] . Moreover, hypoxic microenvironment, a major feature of HNSCC, plays a pivotal role in the emergence of CTCs and cancer stem cells (CSCs) [6] . The prognostic impact of CTCs and their central role in the metastatic cascade has been repeatedly demonstrated in many types of cancer [7] [8] [9] and their molecular characterization holds a very strong potential for novel approaches in the therapeutic management of cancer patients [10, 11] . Although rare and exposed to immunemediated destruction, these cells manage to evade the immune system of the host. Therefore, a better understanding of the immunogenicity of these cells and their cross talk with immune cells may shed light to potential immunotherapy opportunities in HNSCC.
Tumor escape from immune-mediated destruction is due to immunosuppressive mechanisms that inhibit T cell activation. Programmed death 1 (PD1) is a negative immune-regulatory checkpoint, a negative signaling receptor expressed on activated T cells and CD4 (þ) CD25 (þ) Foxp3-expressing T regulatory (T-reg) cells [12] . Overexpression of PD-ligand 1 or 2 (PD-L1 or PD-L2) by tumor cells activates the PD1 checkpoint pathway, by engaging to PD1 receptor, and attenuates the immune response [13] . Clinical trials in platinum-refractory recurrent/metastatic HNSCC have demonstrated safety and activity of PD1 checkpoint inhibitors in HNSCC [14] [15] [16] .
Biomarkers are usually assessed only at baseline in different studies. However, it has been demonstrated that cancer treatments such as radiation may induce immune activation and cytokine production in the tumor microenvironment [17] . Therefore, the tumor immune phenotype may evolve in response to different treatments. Towards this direction, a recent study has shown overexpression of PD-L1 in a subset of CTCs in breast cancer patients [18] .
In the present study, we sought to prospectively determine PD-L1 expression in CTCs at baseline, after induction chemotherapy (IC), after cisplatin chemo-radiation and at relapse in a cohort of locally advanced HNSCC patients treated with curative intend at our institution. To achieve this, we first developed and analytically validated a highly sensitive, specific and reproducible RTqPCR assay for the quantification of PD-L1mRNA expression in CTCs. We demonstrate for the first time that detection of CTCs overexpressing PD-L1 at the end of treatment is associated with shorter progression-free survival (PFS) and overall survival (OS) in locally advanced HNSCC.
Patients and methods

Study design
The 'liquid biopsy in HNSCC' project aims to detect and characterize CTCs in patients with HNSCC and examine their prognostic utility. Written informed consent was obtained from all patients before participating in the study. The present study was approved by the Medical Ethical Committee of Attikon University hospital (Athens, Greece) and complies with the principles laid down in the Declaration of Helsinki. In the present report, we present the results obtained from the analysis of 113 HNSCC patients.
An additional cohort of 41 patients with recurrent/metastatic (R/M) HNSCC was included in the study as a test cohort since the likelihood to detect CTCs in R/M setting is higher compared with locally advanced HNSCC. The choice of chemotherapy in R/M patients was at the discretion of the treating physician. Specimens were obtained only at baseline in patients with R/M disease.
Patients with newly diagnosed inoperable HNSCC were eligible if they had histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx deemed unresectable due to technical or organ preservation reasons. Patients were excluded if they had received prior treatment of locally advanced HNSCC; patients with poor performance status (ECOG >2) and other concomitant neoplasms were also included. Tumor size, loco-regional spread and distant metastases were determined according to the TNM classification. Staging examinations included computed tomography (CT) scan of the head and neck and CT scan of the thorax and abdomen. Patients were enrolled before initiation of treatment. All patients were treated with cisplatin chemo-radiotherapy with curative intent. IC with two cycles of TPF (docetaxel, cisplatin, 5-fluorouracil) preceded concurrent chemo-radiotherapy for patient selection when organ preservation approach was pursued or when a rapid response was deemed appropriate. Two cycles of induction TPF were followed by cisplatin chemo-radiotherapy in patients who attained at least a partial response to IC when an organ preservation strategy was pursued. The protocol called for specimen collection at baseline, at the end of IC (week 6), at completion of chemo-radiation (week 15) and at relapse. For all patients the 'end of treatment' samples were obtained 1 week post-completion of concurrent chemoradiotherapy. Assessment of response was carried out 14 days following the second cycle of IC and 12 weeks after completion of cisplatin chemoradiotherapy. During follow-up, patients were investigated (ENT evaluation and CT of neck/chest) every 3 months for the first 2 years and after 24 months every 6 months. P16 protein status, assessed by immunohistochemistry, was used as a surrogate biomarker for human papillomavirus status. The study complied with the REMARK recommendations for tumor marker prognostic studies using biological material (available at http://www. ncbi.nlm.nih.gov/pmc/articles/PMC2361579). A REMARK diagram is shown in supplementary Figure S1 , available at Annals of Oncology online. Finally, a group of 20 healthy donors were used as controls.
Isolation of EpCAM (1) CTCs
For the isolation of EpCAM (þ) CTCs from peripheral blood (30 ml) we followed our previously described protocols [19, 20] .
RNA extraction
Total RNA from the EpCAM (þ) CTC fraction was isolated using the miRNeasy micro kit (QIAGEN, Germany), according to manufacturer's instructions.
cDNA synthesis cDNA synthesis was carried out using the SuperScript TM First-Strand Synthesis System for RT-PCR (Life technologies) according to the manufacturer's protocol, using 7 ll of isolated total RNA as starting template.
RT-qPCR assay for PD-L1
Primer and probe design. We designed in silico the primers and hydrolysis probes for PD-L1 and HPRT (used as a reference gene) using Primer Premier 5.0 software (Premier Biosoft, CA). Our primers and probes were carefully designed to completely avoid primer-dimer formation, false priming sites, formation of hairpin structures and hybridization to genomic DNA, while amplify specifically only PD-L1 and HPRT target genes according to our search in the BLAST Sequence Similarity Search tool (NCBI, NIH). The hydrolysis probe included a 5'-fluorescein (FAM) as a fluorophore covalently attached to the 5'-end of the oligonucleotide probe and a BlackBerry V R Quencher as a quencher at the 3'-end, while the hybridization probe included a 3'-fluorescein (F) donor probe and a 5'-LC acceptor probe. The sequences of primers and probes are available upon request. Preparation of PCR amplicons for evaluation of the analytical sensitivity of the assay. We generated individual PCR amplicons specifically for PD-L1 and HPRT for the evaluation of the analytical sensitivity of the assay, using total RNA from the LNCAP and SKBR-3 cell lines as previously described [19, 20] .
qPCR. qPCR was carried out in the LightCycler
Normalization of qPCR data in clinical samples. qPCR data for PD-L1 expression were normalized in respect to HPRT expression in the same cDNAs, using the 2 -DDCt approach [21] . CTCs isolated through positive immune-magnetic enrichment are not 100% pure; since 'contamination' of PBMC in the EpCAM (þ) CTC fraction could affect PD-L1 assay specificity we evaluated this 'background noise' by analyzing peripheral blood samples from 20 healthy individuals in exactly the same way as patients. We estimated a cut-off based on PD-L1 normalized expression in respect to HPRT expression in this control group. Using this approach we defined a sample as PD-L1 overexpressed (PD-L1 positive) based on the fold change of PD-L1 expression in the EpCAM (þ) CTC fraction in respect to the corresponding EpCAM (þ) fraction in the group of 20 healthy individuals.
CellSearch
TM analysis for PD-L1 expression on CTCs. We first carried out spiking experiments using a known number of SCC47 cells (0, 10, 50 and 100) spiked in 7.5 ml of whole blood, and analyzed them in the FDA-cleared CellSearch TM system according to a recently validated protocol [18] . PD-L1 expression on CTCs was evaluated in peripheral blood of 16 patients with metastatic HNSCC disease using this protocol. For each patient, 30 ml of peripheral blood were collected in three CellSave tubes. Before CellSearch TM analysis, all samples were enriched for CTCs using the EpCAM independent RosetteSep System (Stem Cell Technology), following manufacturer instructions, so that the analysis could be carried out in 7.5 ml tubes, as required by the CellSearch TM .
Statistical analysis
Objective response at the primary site was evaluated using the RECISTmodified criteria and was defined by either complete response or partial response. PFS was defined as the time from registration to the study to documented disease progression or death from other causes. Alive patients without documented events were censored at the time of the last disease evaluation. OS was defined as the time from registration to the study to death from any cause or censored at the time of last contact. The primary objectives of the study were the associations between PD-L1 expression levels at baseline and at completion of treatment with PFS and OS. Frequency and percentage were used to characterize patient demographics and disease characteristics and Fisher's exact test or v 2 tests were used to make comparisons between groups. Event-time distributions were estimated by the Kaplan-Meier method and compared by the logrank test. Univariable and multivariable Cox proportional hazards (PH) models were used to evaluate the relationship between PD-L1 status (high versus low) and event-time distributions, with tumor stage, node's status, smoking, tumor site and age. Parametric and non-parametric tests were used to compare continuous variables between groups. All P-values are two-sided. A level of P < 0.05 is considered statistically significant unless specified otherwise.
Results
Development and analytical validation of the RT-qPCR assay for PD-L1
Limit of detection, linearity and analytical specificity. We evaluated the limit of detection (LOD) and limit of quantification (LOQ) for both PD-L1 and HPRT as copies/ll in the reaction, using PCR amplicons, containing a known number of copies/ll, of each gene. Serial dilutions of these standards in triplicate, ranging from 10 5 to 10 copies/ll showed linearity, with correlation coefficients larger than 0.99 indicating a precise log-linear relationship (supplementary Figure S2 , available at Annals of Oncology online). LOD for both assays was 3 copies/ll and LOQ was 9 copies/ll [22] . Ten different genomic DNAs (50 ng/ll) gave no amplification signal for any of the gene-target transcripts (results not shown). The characteristics of the calibration curves are given in supplementary Table S1 , available at Annals of Oncology online.
Evaluation of intra-and inter-assay precision. Repeatability or intra-assay variance (within-run precision) of the PD-L1 RTqPCR, was evaluated by repeatedly analyzing three cDNA samples corresponding to low, medium and high PD-L1 transcripts, while for HPRT by repeatedly analyzing 4 cDNA samples corresponding to 1, 10, 100 and 1000 SKBR-3 cells/ll in the same assay, in 3 parallel determinations. Intra-assay variance expressed as the CVs (%) of the Cq variance for PD-L1, ranged from 0.84% to 1.2%, while for HPRT ranged from 0.68% to 1.1% (Table 1) . Intra-assay variance expressed as within-run CVs (%) of copies/ ll ranged for PD-L1, from 16% to 20% and for HPRT from 20% to 24% (Table 1) . Reproducibility or inter-assay variance (between-run precision) of the RT-qPCR assays, was evaluated by analyzing the same cDNA samples, for HPRT and PD-L1 that were kept frozen in aliquots at À20 C, over a period of 1 month on four separate assays carried out in 4 different days. Betweenrun CVs were 15.8% for HPRT and 15% for PD-L1 (Table 1) .
PD-L1 expression in the EpCAM
(1) CTC fraction and corresponding EpCAM (2) PBMC fraction in healthy individuals and HNSCC patients 
PD-L1 expression in primary and recurrent/ metastatic HNSCC
To investigate if PD-L1 was overexpressed in the EpCAM (þ) CTC fraction, we first checked a small cohort of 41 patients with recurrent and/or metastatic (R/M) disease, 25 of which had local recurrence and 16 distant metastases. Five out of 41 (12.2%) patients were found positive for PD-L1 overexpression. Among those patients who were positive for PD-L1 overexpression, 4/5 (80%) died, while among those patients who were negative at baseline, 20/36 (55.6%) deceased. Log-rank test showed no significant difference in OS between patients who were positive for PD-L1 overexpression versus those who were not (log-rank v 2 ¼ 0.047, P ¼ 0.829). Considering the diversity of the applied treatments in these patients with R/M disease, no definitive conclusion can be drawn about the prognostic significance of PD-L1 overexpression.
We subsequently enrolled 113 patients with histologically confirmed primary HNSCC to test the prognostic importance of PD-L1 overexpression in the EpCAM (þ) CTC fraction at baseline and at the end of treatment. Among 8 oropharyngeal cancer patients with available tumor specimens for evaluation of p16 protein expression and known PD-L1 overexpression status in the EpCAM (þ) CTC fraction at baseline, 4 (50.0%) were p16 positive and 3/4 (75%) were positive for PD-L1 overexpression at baseline, while none of the four p16 negative patients (0%) were positive for PD-L1 overexpression (Fisher's exact test, P ¼ 0.143); 94/ 113 (83.2%) patients were evaluable for CTC analysis at baseline, 34/57 (54.9%) after IC and 54/106 (50.9%) at the end of chemoradiotherapy (supplementary Figure S1, Figure 1B . Patient clinical characteristics in correlation to PD-L1 status are shown in Table 2 . At baseline 24/94 (25.5%) patients were found positive for PD-L1 overexpression, at the post-IC setting 8/34 (23.5%) patients were positive and at the end of treatment 12/54 (22.2%) patients were positive for PD-L1 overexpression. Patients with missing sample at the end of treatment did not differ from the ones included in the analysis with respect to patient gender, age, tobacco and alcohol use, TNM stage, histological grade and primary tumor site, as assessed by Fisher's exact test (Table 2 ). There was no correlation between PD-L1 expression at any timepoint and basic patient characteristics (Table 2) .
Clinical outcome
Data on response to treatment were available for 73/113 (64.6%) patients. Forty-three out if 73 (58.9%) patients achieved a complete response (CR) post-treatment, 9/73 (12.3%) a partial response, 3/73 (4.1%) stable disease, while 18/73 (24.7%) developed progressive disease during treatment or within the first 3 months post-treatment. Among 18 patients with overexpression of PD-L1 at baseline, 7 (38.9%) achieved a CR posttreatment, whereas among 41 patients who were PD-L1 negative at baseline, 27 (65.9%) achieved a CR post-treatment (Fisher's exact test, P ¼ 0.085). Among 10 patients with overexpression of PD-L1 at the end of treatment, only 2 (20%) achieved a CR, whereas among 35 patients who were PD-L1 negative at the end of treatment, 28 (80%) achieved a CR (Fisher's exact test, P ¼ 0.001). The absence of PD-L1 overexpression at the end of treatment was strongly associated with complete response with an odds ratio ¼ 16.00 (95% CI ¼ 2.76-92.72, P ¼ 0.002).
Thirty-eight patients were assessed for PD-L1 overexpression at both baseline and at the end of treatment. Among them, 13 (34.2%) overexpressed PD-L1 at baseline and 8 (21.1%) overexpressed PD-L1 at the end of treatment. This difference showed only a trend for statistical significance (McNemar test, uncorrected v 2 ¼ 2.778, P ¼ 0.096), considering also the small sample size. Among 25 patients who were PD-L1 negative at baseline, 23 (92.0%) remained negative at the end of treatment, while among 13 patients who overexpressed PD-L1 at baseline, 6 (46.2%) remained positive at the end of treatment. For 16 patients, samples at baseline, after 2 cycles of IC (week 6) and at the end of concurrent chemoradiotherapy (week 15) were available: serial longitudinal changes of PD-L1 expression in CTC can be seen in supplementary Figure S3 , available at Annals of Oncology online.
Survival
At a median follow-up of 18.9 months (range 0. ( Figure 2A and B) . Also, patients with PD-L1 overexpression post-IC did not differ significantly in PFS (log-rank v 2 ¼ 0.835, P ¼ 0.361) and OS (log-rank v 2 ¼ 0.076, P ¼ 0.783) compared with those without PD-L1 overexpression (data not shown). In contrast, patients with PD-L1 overexpression at the end of treatment had poorer PFS (log-rank v 2 ¼ 11.11, P ¼ 0.001) and OS (log-rank v 2 ¼ 19.17, P < 0.001) ( Figure 2C and D) . Cox regression analysis, also revealed the significance of PD-L1 overexpression in the EpCAM (þ) CTC fraction of HNSCC patients after the completion of treatment. Univariate analysis showed a significantly higher risk of progression and death in the PD-L1 positive compared with PD-L1 negative patients. Finally, multivariate Cox regression model confirmed the prognostic value of PD-L1 overexpression in the EpCAM (þ) CTC fraction at the end of treatment of the prediction of PFS and OS, independently from patients' age and sex, smoking behavior, alcohol intake, tumor T stage, nodal status, primary site and histological grade. In Figure 3 , the forest plots of univariate Cox-regression hazard models are shown.
Imaging of PD-L1
(1) CTCs in HNSCC patients using the CellSearch TM system
CTCs are highly heterogeneous, and it is expected that not all CTCs overexpress PD-L1. This has been shown clearly previously for breast cancer [18] using the CellSearch TM system, where in the same breast cancer patients, PD-L1 (þ) and PD-L1 (À) CTCs were detected. Based on these data, we wanted to evaluate the expression of PD-L1 in CTCs of HNSSC patients using the same methodology as previously described [18] , for a limited number of HNSCC patients (n ¼ 16). According to our results, in 8/16 (50%) patients CTCs were detected; however, only a limited number of CTCs (1-2) was detected in peripheral blood of these patients, and only a sub-fraction of these CTCs were PD-L1 (þ) .There were also three cases, where CTCs were detected but these CTCs were negative for PD-L1 expression (Figure 4) . Before the analysis of clinical samples in the CellSearch TM , we also carried out spiking experiments. Our spiking experiments with the HNSCC SCC47 cell line have shown that when 100 SCC47 cells were spiked in 7.5 ml peripheral blood in a Cellsave tube, 98 tumor cells were detected in the CellSearch TM but only 12/98 (12.2%) of these cells were PD-L1 positive. When 50 SCC47 cells were spiked, 59 tumor cells were enumerated and 13/ 59 (22.0%) out of these cells were PD-L1 positive, while when 10 SCC47 cells were spiked, 11 tumor cells were counted and 2/11 (18.2%) cells were PD-L1 positive. No tumor cells were detected in control blood samples (healthy individuals).
Discussion
We developed and evaluated an RT-qPCR assay for PD-L1 mRNA transcripts and applied it to evaluate PD-L1 overexpression in the EpCAM (þ) CTC fraction, isolated from peripheral blood of HNSCC patients.
Many groups including ours have verified the importance of using molecular assays for CTC molecular characterization [19, 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . We have already shown that molecular assays based on real-time PCR carried out in nucleic acids material (RNA or genomic DNA) isolated from the EpCAM (þ) CTC fraction can give valuable information for the molecular characterization of CTC at the gene expression [19, 20] , DNA methylation [24] [25] [26] and DNA mutation level [27] . It is clear that in this approach we are not verifying the presence of CTCs by imaging through immunofluorescence, but through the genetic material isolated from the EpCAM (þ) fraction. This approach has been extensively and successfully used also for the molecular characterization of EpCAM (þ) CTCs in breast and ovarian cancer patients by other research groups [28] [29] [30] . Direct comparison studies of our system with this commercially available test have shown satisfactory correlations when the same samples were analyzed by both methodologies [31] . In the present study, we sought to determine the prognostic significance of PD-L1 overexpression in the EpCAM (þ) CTC fraction at baseline and at the end of definitive treatment in locally advanced HNSCC. The use of chemotherapy as adjuvant/consolidation treatment has not yielded survival improvement in HNSCC [33] [34] [35] . However, the more recent advent of targeted therapies urges re-examination of the question of adjuvant/consolidation systemic therapy following the completion of chemo-radiation. This concept has been successfully applied in breast cancer where 1 year of treatment with the HER2-targeted monoclonal antibody trastuzumab following adjuvant chemotherapy for early HER2 (þ) breast cancer represents currently the standard of care for these patients [36] .The decision on adjuvant therapy in cancer is currently based on the characteristics of the primary tumor. However, the aim of administering adjuvant therapy in cancer is considered to be the eradication of minimal residual disease, which is present after primary surgery but undetectable by currently used conventional imaging approaches. It is therefore possible that decision on adjuvant therapy should be based on the detection and molecular characterization of CTCs [37] .
Recent studies indicate that evaluation of PD-L1 protein status in tumor specimens could assist in patient selection for treatment with PD1 checkpoint inhibitors [38] . However, accurate measurement of PD-L1 protein levels in FFPE tumor samples, as discussed previously, is limited by the absence of reliable antibodies and interpretative uncertainties (i.e. positivity cutoff). Another limitation of PD-L1 expression assessment on tumor biopsies is tumor heterogeneity. Several studies have demonstrated discordance in biomarker expression between primary tumor and CTCs [27, 29] indicating that heterogeneous clones exist that are often not represented in the biopsy material.
It appears, therefore, that liquid biopsies provide a non-invasive tool for molecular characterization of tumors which can be more informative than serial tumor biopsies. A very recent study has shown for the first time that PD-L1 protein status can be evaluated in CTCs of breast cancer patients with verified metastasis by using the FDA cleared CellSearch TM system [18] . Other studies have also shown PD-L1 protein expression on CTCs in patients with bladder cancer [39] and NSCLC [40] . However, the evaluation of PD-L1 protein status using immunofluorescence is strongly affected by the specificity of antibodies used and interpretative uncertainties (i.e., positivity cutoff), unless a robust validation of the antibody is carried out [18] . Nicolazzo Figure 3 . Forest plots of univariate Cox models for (A) OS and (B) PFS for HNSCC patients at the end of the treatment.
[40]. According to this study, all patients with PD-L1 (À) CTCs obtained a clinical benefit, while all patients with PD-L1 (þ) CTCs experienced progressive disease. Thus the persistence of PD-L1 (þ) CTCs is indicative of a mechanism of therapy escape. Therefore, liquid biopsy may allow real-time sampling of patients for PD-L1 through the course of the disease and provide information on mechanisms of tumor escape and response to immunotherapy.
By using this novel molecular assay, we demonstrate for the first time to our knowledge, in a cohort of locally advanced HNSCC treated with definitive non-surgical treatment including chemoradiation þ IC, that detection of CTCs over-expressing PD-L1 at the end of definitive treatment correlates with lower likelihood of attaining CR and higher risk for progression and death compared with PD-L1 negative counterparts. Our results raise the question on whether PD1 targeted therapies can eliminate PD-L1 over-expressing CTCs and increase cure rates in locally advanced HNSCC patients in whom PD-L1 over-expressing CTCs are detected at the end of definitive treatment. Our results also demonstrate that serial PD-L1 expression assessment in liquid biopsies is feasible and has potential to select and monitor patients for PD1 inhibitors. Because therapy with checkpoint inhibitors is cost intensive, cancer-bearing patients who may benefit from such treatments must be properly selected using appropriate biomarkers. This approach underscores the crucial need for predictive biomarkers that can be introduced in the clinical routine. Although studies of combination of chemotherapy and immunotherapy are being planned, the important question of how to integrate these novel therapies with the current clinical strategy still remains. This highlights the need to develop clear immune biological and clinical parameters that allow for rapid go/no-go decisions.
In the present study, we observed that PD-L1 expression in the EpCAM (þ) CTC fraction may evolve during treatment and this modulation may inform clinical trial design of the sequence of chemotherapy and/or radiation with immunotherapy.
A major limitation of our study is that it is a single institution cohort and our results need to be validated in larger cohorts. In addition, EpCAM-based isolation methods may miss CTCs bearing mesenchymal rather than epithelial phenotype, a phenomenon that is not uncommon in HNSCC.
Since our RT-qPCR assay does not enumerate CTCs, a relevant question could be whether our findings are related to the extent of minimal residual disease (i.e. number of CTCs) at the end of treatment rather than the prognostic importance of PD-L1 expression on CTCs as a biomarker. To answer this question, we evaluated PD-L1 expression on CTCs in peripheral blood samples for a limited number of HNSCC patients, using direct imaging through the CellSearch TM system. Previous experiments using the CellSearch TM system in breast cancer demonstrated that the percentage of CTCs expressing PD-L1is not directly correlated with the total number of CTCs since in the same breast cancer patients, there were PD-L1
(þ) and PD-L1 (À) CTCs [18] . CTCs are indeed highly heterogeneous thus it is expected that not all CTCs overexpress PD-L1. Indeed our data verify this finding in HNSCC as well, since we have found that only a subset of CTCs detected were PD-L1 (þ) while there were also cases, where CTCs were detected but were negative for PD-L1 expression.
In summary, we demonstrate that serial determination of PD-L1 expression in the EpCAM (þ) CTC fraction is feasible and may inform clinical trial design.
